These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12513924)

  • 41. Lipopeptide stimulation of MHC class I-restricted memory cytotoxic T lymphocytes from equine infectious anemia virus-infected horses.
    Ridgely SL; McGuire TC
    Vaccine; 2002 Mar; 20(13-14):1809-19. PubMed ID: 11906769
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunology of a persistent retrovirus infection--equine infectious anemia.
    McGuire TC; Crawford TB
    Adv Vet Sci Comp Med; 1979; 23():137-59. PubMed ID: 95154
    [No Abstract]   [Full Text] [Related]  

  • 43. An attenuated EIAV vaccine strain induces significantly different immune responses from its pathogenic parental strain although with similar in vivo replication pattern.
    Lin YZ; Shen RX; Zhu ZY; Deng XL; Cao XZ; Wang XF; Ma J; Jiang CG; Zhao LP; Lv XL; Shao YM; Zhou JH
    Antiviral Res; 2011 Nov; 92(2):292-304. PubMed ID: 21893100
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of EIAV immunogenicity during persistent infections: humoral responses and antigen targets.
    Montelaro RC; Ball JM; Issel CJ
    Dev Biol Stand; 1990; 72():19-30. PubMed ID: 1704323
    [No Abstract]   [Full Text] [Related]  

  • 45. The efficacy of ELISA commercial kits for the screening of equine infectious anemia virus infection.
    Alvarez I; Cipolini F; Wigdorovitz A; Trono K; Barrandeguy ME
    Rev Argent Microbiol; 2015; 47(1):25-8. PubMed ID: 25735214
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Equine infectious anemia--recent researches and prospect of the study (author's transl)].
    Kono Y
    Uirusu; 1973 Mar; 23(1):1-12. PubMed ID: 4356439
    [No Abstract]   [Full Text] [Related]  

  • 47. Complement fixation test of equine infectious anemia. II. Relationship between CF antibody response and the disease.
    Kono Y; Kobayashi K
    Natl Inst Anim Health Q (Tokyo); 1966; 6(4):204-7. PubMed ID: 4292232
    [No Abstract]   [Full Text] [Related]  

  • 48. Role of the host immune response in selection of equine infectious anemia virus variants.
    Carpenter S; Evans LH; Sevoian M; Chesebro B
    J Virol; 1987 Dec; 61(12):3783-9. PubMed ID: 2446008
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A review of antigenic variation by the equine infectious anemia virus.
    McGuire TC; O'Rourke K; Cheevers WP
    Contrib Microbiol Immunol; 1987; 8():77-89. PubMed ID: 3040337
    [No Abstract]   [Full Text] [Related]  

  • 50. In vitro antibody-dependent enhancement assays are insensitive indicators of in vivo vaccine enhancement of equine infectious anemia virus.
    Raabe ML; Issel CJ; Montelaro RC
    Virology; 1999 Jul; 259(2):416-27. PubMed ID: 10388665
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hyperglobulinemia and lymphocyte subset changes in naturally infected, inapparent carriers of equine infectious anemia virus.
    Russell KE; Walker KM; Miller RT; Sellon DC
    Am J Vet Res; 1998 Aug; 59(8):1009-15. PubMed ID: 9706205
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunization of horses against equine infectious anemia (EIA) with an attenuated EIA virus.
    Kono Y; Kobayashi K; Fukunaga Y
    Natl Inst Anim Health Q (Tokyo); 1970; 10(3):113-22. PubMed ID: 4320652
    [No Abstract]   [Full Text] [Related]  

  • 53. Structural proteins of equine infectious anemia virus and their antigenic activity.
    Nishimura M; Nakajima H
    Am J Vet Res; 1984 Jan; 45(1):5-10. PubMed ID: 6322625
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Response of ELA-A1 horses immunized with lipopeptide containing an equine infectious anemia virus ELA-A1-restricted CTL epitope to virus challenge.
    Ridgely SL; Zhang B; McGuire TC
    Vaccine; 2003 Jan; 21(5-6):491-506. PubMed ID: 12531649
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Failure of low-dose recombinant human IL-2 to support the survival of virus-specific CTL clones infused into severe combined immunodeficient foals: lack of correlation between in vitro activity and in vivo efficacy.
    Mealey RH; Littke MH; Leib SR; Davis WC; McGuire TC
    Vet Immunol Immunopathol; 2008 Jan; 121(1-2):8-22. PubMed ID: 17727961
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Equine infectious anemia virus from infected horse serum.
    Nakajima H; Yoshino T; Ushimi C
    Infect Immun; 1974 Sep; 10(3):667-8. PubMed ID: 4372175
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunopathogenesis of equine infectious anemia lentivirus disease.
    McGuire TC; O'Rourke KI; Perryman LE
    Dev Biol Stand; 1990; 72():31-7. PubMed ID: 2178127
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Complement fixation test of equine infectious anemia. I. Specificity of the test.
    Kono Y; Kobayashi K
    Natl Inst Anim Health Q (Tokyo); 1966; 6(4):194-203. PubMed ID: 4292231
    [No Abstract]   [Full Text] [Related]  

  • 59. Monocyte activation in horses persistently infected with equine infectious anemia virus.
    Banks KL
    Infect Immun; 1975 Nov; 12(5):1219-21. PubMed ID: 172455
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antigenic stimulation of T lymphocytes in chronic nononcogenic retrovirus infection: equine infectious anemia.
    Shively MA; Banks KL; Greenlee A; Klevjer-Anderson P
    Infect Immun; 1982 Apr; 36(1):38-46. PubMed ID: 6281191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.